| scholarly article | Q13442814 |
| P50 | author | Linda A Sherman | Q42403205 |
| P2093 | author name string | Cheever MA | |
| Disis ML | |||
| Peterson P | |||
| LaFace D | |||
| Theobald M | |||
| Lustgarten J | |||
| Labadie C | |||
| P2860 | cites work | A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma | Q24319940 |
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| The subcellular localization of the neu protein in human normal and neoplastic cells | Q35573517 | ||
| The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas | Q36362111 | ||
| Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines | Q36364998 | ||
| Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes | Q36365159 | ||
| Human CD8 transgene regulation of HLA recognition by murine T cells | Q36365522 | ||
| Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines | Q36366108 | ||
| Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules | Q36741865 | ||
| Antigen recognition by class I-restricted T lymphocytes | Q38201551 | ||
| Cytokines and clinical gene therapy | Q40517546 | ||
| Tumor antigens recognized by T lymphocytes | Q40661131 | ||
| Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes | Q41483867 | ||
| Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the HER-2/neu Proto-oncogene | Q41525509 | ||
| Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response | Q42263474 | ||
| The neu oncogene encodes an epidermal growth factor receptor-related protein | Q42812960 | ||
| Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex | Q42941471 | ||
| The alpha 3 domain of major histocompatibility complex class I molecules plays a critical role in cytotoxic T lymphocyte stimulation | Q43689709 | ||
| Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. | Q43745715 | ||
| Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2. | Q46302372 | ||
| Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor | Q48369441 | ||
| Interferon-gamma-induced increased sensitivity of HER2/neu-overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events | Q54230494 | ||
| Strong xenogeneic HLA response in transgenic mice after introducing an α3 domain into HLA B27 | Q59097178 | ||
| Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes | Q67533330 | ||
| Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. comparison with anti-proliferative activity by RIL1-β, RTNF-α, RIFN-γ, RIl4 and their combinations | Q67654038 | ||
| Study of Tumor-Infiltrating Lymphocytes for Adoptive Therapy of Renal Cell Carcinoma (RCC) and Metastatic Melanoma: Sequential Proliferation of Cytotoxic Natural Killer and Noncytotoxic T Cells in RCC | Q67856841 | ||
| Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice | Q67966175 | ||
| Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues | Q68083841 | ||
| A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein | Q68157843 | ||
| Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice | Q70911259 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 109-118 | |
| P577 | publication date | 1997-02-01 | |
| P1433 | published in | Human Immunology | Q15709955 |
| P1476 | title | Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. | |
| P478 | volume | 52 |
| Q40864858 | A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes |
| Q50260488 | A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice |
| Q40840298 | A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals |
| Q38633206 | Adjuvant HER2/neu peptide cancer vaccines in breast cancer |
| Q78007114 | Analysis of protooncogene c-erbB-2 in benign and malignant human prostate |
| Q34105959 | Anti-HER2 vaccines: new prospects for breast cancer therapy |
| Q34038749 | Antitumor vaccination using peptide based vaccines. |
| Q42683276 | Breast Cancer Vaccines: New Insights |
| Q36015421 | CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers |
| Q37882478 | Camouflage and sabotage: tumor escape from the immune system |
| Q34386193 | Cancer immunotherapy: insights from transgenic animal models |
| Q33586656 | Cancer vaccines: novel approaches and new promise |
| Q34956133 | Cellular immunity to the Her-2/neu protooncogene |
| Q26745440 | Clinical Development of the E75 Vaccine in Breast Cancer |
| Q36648360 | Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours |
| Q51490010 | Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants |
| Q31155972 | Discovery and characterization of highly immunogenic and broadly recognized mimics of the HIV-1 CTL epitope Gag77-85. |
| Q34999946 | Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates. |
| Q36487452 | Enzymatic Discovery of a HER-2/neu Epitope That Generates Cross-Reactive T Cells |
| Q92060838 | Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data |
| Q40161787 | HLA-A2.1-restricted T cells react to SEREX-defined tumor antigen CML66L and are suppressed by CD4+CD25+ regulatory T cells |
| Q40759589 | Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen |
| Q35806782 | Immunity, cancer and aging: lessons from mouse models |
| Q37963294 | Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses |
| Q46820235 | Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. |
| Q38807849 | Peptide-Based Cancer Vaccine Strategies and Clinical Results |
| Q40953949 | Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. |
| Q37316604 | Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family |
| Q24815775 | T cell avidity and tumor recognition: implications and therapeutic strategies |
| Q41642406 | T cell defined tumor antigens |
| Q93039761 | Targeting Cancer with Genetically Engineered TCR T Cells |
| Q40584258 | The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity |
| Q35181440 | The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. |
| Q45974146 | The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors |
| Q36401780 | The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope |
| Q35081106 | The application of electroporation to transfect hematopoietic cells and to deliver drugs and vaccines transcutaneously for cancer treatment |
| Q38885965 | The development and use of the E75 (HER2 369-377) peptide vaccine |
| Q77419028 | The effect of human beta2-microglobulin on major histocompatibility complex I peptide loading and the engineering of a high affinity variant. Implications for peptide-based vaccines |
| Q77813558 | The use of human leucocyte antigen class I transgenic mice to investigate human immune function |
| Q24801995 | Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition |
Search more.